Optimisation of Ultra-Small Volume Adenosine, Lidocaine and Mg2+ (ALM) Fluid Resuscitation and 72hr Stabilisation Drip for Uncontrolled Haemorrhage and TBI (Old ID 23011)

Chief Investigator

The resuscitation and stabilisation properties of ALM 'one-two treatment' will be investigated in rats after uncontrolled blood loss ± traumatic brain injury, and a translational arm in pigs followed for 72hrs to mimic prolonged far-forward retrieval delays. The aim is to show improved survival is associated with improved cardiac function, reduced inflammation, less coagulopathy and less secondary 'it' complications. The ALM therapy has the potential to reduce morbidity and mortality on the battlefield by buying time for treatment, stabilisation and preparedness of causalities for safer evacuation. The study also has broad-spectrum public purpose for pre-hospital trauma and aeromedical transport.

26 Sep 2016 - 25 Dec 2020

N/A